
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6168934/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study. Current Oncology, 2022, 29, 433-438.	0.9	1
2	Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments. Cancers, 2022, 14, 2408.	1.7	15
3	Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease. Journal of Experimental and Clinical Cancer Research, 2021, 40, 49.	3.5	11
4	Detection and Investigation of Extracellular Vesicles in Serum and Urine Supernatant of Prostate Cancer Patients. Diagnostics, 2021, 11, 466.	1.3	12
5	Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient. Frontiers in Medicine, 2021, 8, 689895.	1.2	4
6	Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue. Biomedicines, 2021, 9, 1242.	1.4	6
7	A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera. Cancers, 2021, 13, 4968.	1.7	0
8	Early Detection and Investigation of Extracellular Vesicles Biomarkers in Breast Cancer. Frontiers in Molecular Biosciences, 2021, 8, 732900.	1.6	4
9	Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?. Frontiers in Medicine, 2021, 8, 725346.	1.2	Ο
10	MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 13357.	1.8	6
11	CNA Profiling of Single CTCs in Locally Advanced Esophageal Cancer Patients during Therapy Highlights Unexplored Molecular Pathways. Cancers, 2021, 13, 6369.	1.7	2
12	Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?. Frontiers in Medicine, 2021, 8, 725346.	1.2	3
13	Know your enemy: Genetics, aging, exposomic and inflammation in the war against triple negative breast cancer. Seminars in Cancer Biology, 2020, 60, 285-293.	4.3	16
14	Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer. Cancers, 2020, 12, 2490.	1.7	25
15	CDKN1A upregulation and cisplatinâ€pemetrexed resistance in non‑small cell lung cancer cells. International Journal of Oncology, 2020, 56, 1574-1584.	1.4	19
16	CTCs 2020: Great Expectations or Unreasonable Dreams. Cells, 2019, 8, 989.	1.8	29
17	Adipocytes and microRNAs Crosstalk: A Key Tile in the Mosaic of Breast Cancer Microenvironment. Cancers, 2019, 11, 1451.	1.7	20
18	Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 863-871.	1.1	14

#	Article	IF	CITATIONS
19	Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH. Journal of Visualized Experiments, 2017, , .	0.2	4
20	Circulating Tumor Cells: Back to the Future. Frontiers in Oncology, 2017, 6, 275.	1.3	3
21	DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. OncoTargets and Therapy, 2017, Volume 10, 4657-4664.	1.0	3
22	Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. Oncotarget, 2017, 8, 2423-2436.	0.8	24
23	Circulating Tumor Cells in the Adenocarcinoma of the Esophagus. International Journal of Molecular Sciences, 2016, 17, 1266.	1.8	13
24	CTCs in early breast cancer: A path worth taking. Cancer Letters, 2016, 376, 205-210.	3.2	28
25	IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. Journal of Translational Medicine, 2015, 13, 229.	1.8	23
26	Epithelial Mesenchymal Transition: a doubleâ€edged sword. Clinical and Translational Medicine, 2015, 4, 14.	1.7	107
27	Circulating tumor cells in early breast cancer: A connection with vascular invasion. Cancer Letters, 2015, 367, 43-48.	3.2	34
28	CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. Bone, 2014, 66, 214-222.	1.4	28
29	Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Annals of Translational Medicine, 2014, 2, 109.	0.7	84
30	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Letters, 2013, 335, 225-231.	3.2	208
31	Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines. International Journal of Oncology, 2013, 42, 1263-1270.	1.4	20
32	Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer. Current Cancer Drug Targets, 2012, 12, 940-949.	0.8	27
33	Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell International, 2012, 12, 48.	1.8	19
34	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori, 2012, 98, 696-701.	0.6	17
35	Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. Journal of Cellular Physiology, 2012, 227, 3389-3396.	2.0	24
36	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori, 2012, 98, 696-701.	0.6	6

#	Article	IF	CITATIONS
37	Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. Journal of Cellular and Molecular Medicine, 2011, 15, 316-326.	1.6	5
38	Activity of different anthracycline formulations in hormoneâ€refractory prostate cancer cell lines: Role of golgi apparatus. Journal of Cellular Physiology, 2011, 226, 3035-3042.	2.0	7
39	Abstract 5167: A new panel of tissue markers for the prediction of bone metastatization from primary breast cancer. , 2011, , .		Ο
40	Abstract 4901: Preliminary investigation of circulating NSCLC cells using dielectrophoresis-based instrumentation. , 2011, , .		0
41	Docetaxel–ST1481 sequence exerts a potent cytotoxic activity on hormoneâ€resistant prostate cancer cells by reducing drug resistanceâ€related gene expression. Prostate, 2010, 70, 219-227.	1.2	10
42	Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells. Current Cancer Drug Targets, 2010, 10, 422-431.	0.8	19
43	Role of RAF/MEK/ERK pathway, pâ€STATâ€3 and Mclâ€1 in sorafenib activity in human pancreatic cancer cell lines. Journal of Cellular Physiology, 2009, 220, 214-221.	2.0	69
44	Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. Anti-Cancer Drugs, 2009, 20, 918-925.	0.7	12
45	Mitotic catastrophe and apoptosis induced by docetaxel in hormoneâ€refractory prostate cancer cells. Journal of Cellular Physiology, 2008, 217, 494-501.	2.0	51
46	Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. Journal of Translational Medicine, 2008, 6, 43.	1.8	24
47	NCX 4040, an NO-donating acetylsalicylic acid derivative: Efficacy and mechanisms of action in cancer cells. Nitric Oxide - Biology and Chemistry, 2008, 19, 225-236.	1.2	27
48	Role of p53 Codon 72 Arginine Allele in Cell Survival in vitro and in the Clinical Outcome of Patients with Advanced Breast Cancer. Tumor Biology, 2008, 29, 145-151.	0.8	19
49	Phase I Study of Paclitaxel and Uracil plus Tegafur Combination in Patients with Pretreated Metastatic Breast Cancer: Drug Sequencing Based on Preclinical Modelling Studies. Oncology, 2007, 72, 118-124.	0.9	8
50	Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. Journal of Translational Medicine, 2007, 5, 52.	1.8	19
51	Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics. Journal of Cellular Physiology, 2007, 212, 710-716.	2.0	11
52	Short Interfering RNA Directed against the SLUG Gene Increases Cell Death Induction in Human Melanoma Cell Lines Exposed to Cisplatin and Fotemustine. Analytical Cellular Pathology, 2007, 29, 279-287.	0.7	15
53	Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study. BMC Cell Biology, 2006, 7, 6.	3.0	60
54	Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines*. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1321-1330.	2.2	33

#	Article	IF	CITATIONS
55	p16INK4A andCDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. Journal of Cellular Physiology, 2006, 206, 611-615.	2.0	66
56	Efficacy of a nitric oxide–releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Molecular Cancer Therapeutics, 2006, 5, 919-926.	1.9	43
57	Cellular Basis of Antiproliferative and Antitumor Activity of the Novel Camptothecin Derivative, Gimatecan, in Bladder Carcinoma Models. Neoplasia, 2005, 7, 152-161.	2.3	16
58	Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 1095-1103.	2.2	35
59	Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT). Journal of Biotechnology, 2005, 118, 370-378.	1.9	9
60	In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. Journal of Translational Medicine, 2005, 3, 7.	1.8	33
61	Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Research, 2005, 7, R681-9.	2.2	63
62	Schedule-Dependent Cytotoxic Interaction between Epidoxorubicin and Gemcitabine in Human Bladder Cancer Cells in Vitro. Clinical Cancer Research, 2004, 10, 1500-1507.	3.2	25
63	Drosophila vitelline membrane cross-linking requires the fs(1)Nasrat, fs(1)polehole and chorion genes activities. Development Genes and Evolution, 2001, 211, 573-580.	0.4	30